https://schwabnetwork.com/video/nvda-price-target-hikes-nvo-gains-on-wegovy-fda-approval-day-up-over-25-
NVDA Price Target Hikes, NVO Gains on Wegovy FDA Approval, DAY Up Over 25% | Schwab Network
Novo Nordisk (NVO) jumped higher after the FDA approved the company's Wegovy drug as a liver disease treatment. Dayforce (DAY) rallied more than 25% off...
nvda pricefda approvalschwab networktargethikes